Galmed Pharmaceuticals prices USD7 Million Public Offering
Categories: Capital Markets
Israel-headquartered Galmed Pharmaceuticals, a public, clinical stage biopharmaceutical company focused on the development of Aramchol for liver and fibro-inflammatory diseases, has issued a follow-on public offering of ordinary shares and warrants.
Greenberg Traurig Tel Aviv and NYC advised Galmed, led by Tel Aviv shareholder Gary Emmanuel, with the support of fellow shareholders David Huberman and Eyal Peled, and associates Michael Soumas, Omer Gamlieli and Eran Levy.
Meitar advised as Israel counsel, with Ellenoff Grossman & Schole LLP, acting as placement agent U.S. counsel), and
Sullivan & Worcester (placement agent, Israeli counsel).
